Tyrosine kinase inhibitors (TKI): nilotinib
Evidence-based neurology checklist on tyrosine kinase inhibitors (tki): nilotinib: Neurological complications Headache Cognitive impairment Dystonia Intracranial vascular stenosis Rapidly progressive vasculopathy Stroke Myasthenia gravis (MG) Dermatological complications Cardiac complications…
Neurological complications
- Headache
- Cognitive impairment
- Dystonia
- Intracranial vascular stenosis
- Rapidly progressive vasculopathy
- Stroke
- Myasthenia gravis (MG)
Dermatological complications
Cardiac complications
Vascular complications
Pulmonary complications
Gastrointestinal complications
Haematological complications
Metabolic complications
References
- Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008; 30:1956-1975.
- Chan J, Shah P, Moguel-Cobos G. Nilotinib-induced dystonia and cognitive deficits in a neurologically normal patient with chronic myeloid leukemia. Case Rep Neurol Med 2019; 2019:3679319.
- Chen CJ, Sorace BJ, Shakeri A, et al. Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. J Neurointerv Surg 2018; 10:e28.
- Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M. Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia. Interv Neuroradiol 2017; 23:527-530.
- Suh KJ, Lee JY, Shin DY, et al. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int J Hematol 2017; 106:229-239.
- And 17 more. Subscribe to see the full list
